Trials / Completed
CompletedNCT00646958
Safety and Efficacy Study of Oxazolidinones to Treat Uncomplicated Skin Infections
A Phase 2, Multicenter, Randomized, Open-Label, Comparative Study to Evaluate the Safety and Efficacy of RX-1741 Versus Linezolid in the Outpatient Treatment of Adult Patients With Uncomplicated Skin and Skin Structure Infection
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 150 (actual)
- Sponsor
- Melinta Therapeutics, Inc. · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to assess the efficacy, safety and tolerability of RX-1741, an oxazolidinone, versus linezolid, another oxazolidinone, in the treatment of uncomplicated skin and skin structure infections
Conditions
- Infectious Skin Diseases
- Bacterial Skin Diseases
- Staphylococcal Skin Infections
- Streptococcal Infections
- Abscess
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Radezolid | 450mg PO QD |
| DRUG | Radezolid | 450mg PO BID |
| DRUG | Linezolid | 600mg PO BID |
Timeline
- Start date
- 2007-12-01
- Primary completion
- 2008-04-01
- Completion
- 2008-04-01
- First posted
- 2008-03-31
- Last updated
- 2014-03-27
- Results posted
- 2009-06-26
Locations
19 sites across 1 country: United States
Source: ClinicalTrials.gov record NCT00646958. Inclusion in this directory is not an endorsement.